Epicept förbereder sig för global lansering av Ceplene m.m
2009-04-14 07:12, Edited at: 2010-06-11 12:10Please note: Community posts are written by its members and not by Redeye’s research department. As a reader you’re always encouraged to critically analyze the content.
I min föregående blogg skrev jag att Epicept nu förbereder sig för introduktionen av Ceplene på den amerikanska marknaden via en intressant nyrekrytering. Mycket av det jag skrev i påskhelgen bekräftas via denna pressrelease som nu kom från Epicept:
http://investor.epicept.com/releasedetail.cfm?ReleaseID=376898
Ett utdrag:
"We are delighted that Dr. Smyth has decided to join our Board of Directors," stated Robert Savage, Chairman of the Board of Directors. "It is a tremendous opportunity to be able to bring someone with his wealth of expertise and experience in the field of oncology to the EpiCept Board, particularly as the company prepares for the launch in Europe of Ceplene(R) (histamine dihydrochloride) with a commercial partner. Dr. Smyth will also be an invaluable asset to EpiCept as it pursues regulatory approval for Ceplene in other key global markets and advances its promising earlier-stage oncology compound crinobulin."
Allt väl så långt. Nu är det dags att avtalet för försäljning av Ceplene i Europa landar.
Med vänlig hälsning
el julio